Cat. #161683
Fibroblast specific Spag17 knockout mouse
Cat. #: 161683
Availability: 3-4 weeks
Disease: Fibrocystic disease; Systemic sclerosis
Model: Knock-out
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Maria E Teves Ph.D., Jerome F Strauss III M.D Ph.D., and John Varga M.D.
Institute: Virginia Commonwealth University
Primary Citation: Sapao et al. J Invest Dermatol. 143(2):284-293 PMID: 36116512
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Tool name: Fibroblast specific Spag17 knockout mouse
- Research fields: Systemic sclerosis and fibrosis
- Disease: Fibrocystic disease; Systemic sclerosis
- Model: Knock-out
- Crispr: No
- Description: This is a fibroblast specific, Tamoxifen inducible knockout mouse model for the deletion of the Spag17 gene. Reserachers identified the Spag17 gene as one differentially regulated in fibrotic diseases and created a mouse model was created with inducible fibroblast specific Spag17 knockout. Knockout Spag17 mice show significant fibrosis in skin, heart, lungs, kidneys, and skeletal muscle between 4-6 months of age. These mice have greater collagen deposition, enhanced fibroblast to myofibro...
- Phenotype: Multi-organ fibrosis
References
- Sapao et al. J Invest Dermatol. 143(2):284-293 PMID: 36116512
